ArticleJournal of endocrinological investigation2026
Prevalence and impact of fibromyalgia on patients with type 2 diabetes: a large-scale real-world data analysis.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeFibromyalgia is common in type 2 diabetes (T2D). However, its prevalence and impact on T2D-related complications, particularly in large-scale settings, remain unclear. This study estimated the prevalence of fibromyalgia in T2D and its impact on T2D-related complications.
methodsThis retrospective cohort study used TriNetX data. We defined the T2D cohort by using International Classification of Diseases, Tenth Revision codes, and we estimated the prevalence of fibromyalgia in this cohort for the period between June 1, 2019, and June 1, 2024. We defined patients with T2D and fibromyalgia as Cohort 1 and patients with T2D but without fibromyalgia as Cohort 2. We then performed 1:1 propensity score matching between the two cohorts. In July 2024, we conducted risk analyses (measured through odds ratios) and survival analyses by using the built-in algorithms on the TriNetX platform.
resultsThe overall prevalence of fibromyalgia was 4.03% in patients with T2D (6.16% and 1.65% in women and men, respectively). Patients aged 45–49 and 50–54 years had the highest prevalence of fibromyalgia. Cohort 1 exhibited approximately 20% to 90% higher cumulative odds of T2D-related complications compared with Cohort 2. These complications included cardiovascular disease, major adverse cardiac events, ischemic heart disease, coma, ophthalmic disease, nephropathy, neuropathy, and foot ulcers. Additionally, the instantaneous risk of these complications, with the exception of nephropathy, was higher in Cohort 1 than in Cohort 2.
conclusionThis study estimated the prevalence of fibromyalgia in T2D and indicated that fibromyalgia might augment T2D-related complications.
Indexed as
Identifiers
41591731What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.